Without product out the door they have around 5 quarters of working capital based on 4Q income statement and reducing R&D by 30% and SG&A by 20% on an annualized basis. That projection does not include any CAPEX. I am assuming 13.5 in Revenue.
I estimate they have 180 employees assigned to manufacturing and if you assign a cost of 110K per employee annually that would be a 19.8M Cost. If the lower volume per unit syringe cost is say .75 cents that would give a gross sales of 22.2M. You would need to subtract material and overhead from that .75 cents but you would recapture a large part of the labor you are now paying for through R&D. Recapturing that labor cost is what will reduce UNS cash burn immensely. You would not see a gross profit however overall operating cost will be reduced significantly.
Remember Gross profit pays for the SG&A and R&D (which no longer includes manufacturing as part of R&D)
- Forums
- ASX - By Stock
- UNS
- May 31 Approaching
May 31 Approaching, page-10
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online